Search results

28 results

Sorted by Relevance . Sort by Date

  1. Implantable cardiac monitors to detect atrial fibrillation after cryptogenic stroke (DG41)

    Evidence-based recommendations on implantable cardiac monitors to detect atrial fibrillation after cryptogenic stroke

  2. Suspected cancer: recognition and referral (NG12)

    This guideline covers identifying children, young people and adults with symptoms that could be caused by cancer. It outlines appropriate investigations in primary care, and selection of people to refer for a specialist opinion. It aims to help people understand what to expect if they have symptoms that may suggest cancer.

  3. Low back pain and sciatica in over 16s: assessment and management (NG59)

    This guideline covers assessing and managing low back pain and sciatica in people aged 16 and over. It outlines physical, psychological, pharmacological and surgical treatments to help people manage their low back pain and sciatica in their daily life. The guideline aims to improve people’s quality of life by promoting the most effective forms of care for low back pain and sciatica.

  4. Neuropathic pain in adults: pharmacological management in non-specialist settings (CG173)

    This guideline covers managing neuropathic pain (nerve pain) with pharmacological treatments (drugs) in adults in non-specialist settings. It aims to improve quality of life for people with conditions such as neuralgia, shingles and diabetic neuropathy by reducing pain and promoting increased participation in all aspects of daily living. The guideline sets out how drug treatments for neuropathic pain differ from traditional pain management.

  5. Rheumatoid arthritis in adults: management (NG100)

    This guideline covers diagnosing and managing rheumatoid arthritis. It aims to improve quality of life by ensuring that people with rheumatoid arthritis have the right treatment to slow the progression of their condition and control their symptoms. People should also have rapid access to specialist care if their condition suddenly worsens.

  6. Acute coronary syndromes (NG185)

    This guideline covers the early and longer-term (rehabilitation) management of acute coronary syndromes. These include ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI) and unstable angina. The guideline aims to improve survival and quality of life for people who have a heart attack or unstable angina.

  7. Avelumab with axitinib for untreated advanced renal cell carcinoma (TA645)

    Evidence-based recommendations on avelumab (Bavencio) with axitinib (Inlyta) for untreated advanced renal cell carcinoma in adults

  8. Pembrolizumab with axitinib for untreated advanced renal cell carcinoma (TA650)

    Evidence-based recommendations on pembrolizumab (Keytruda) with axitinib (Inlyta) for untreated advanced renal cell carcinoma in adults

  9. Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma (TA649)

    Evidence-based recommendations on polatuzumab vedotin (Polivy) with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma

  10. Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy (TA655)

    Evidence-based recommendations on nivolumab (Opdivo) for advanced squamous non-small-cell lung cancer in adults after chemotherapy

  11. Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer (TA654)

    Evidence-based recommendations on osimertinib (Tagrisso) for untreated locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive

  12. Drug-eluting stents for the treatment of coronary artery disease (TA152)

    Evidence-based recommendations on using drug-eluting stents in adults

  13. Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma (TA658)

    Evidence-based recommendations on isatuximab (Sarclisa) with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma in adults

  14. Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer (TA660)

    Evidence-based recommendations on darolutamide (Nubeqa) for treating hormone-relapsed prostate cancer in adults at high risk of developing metastatic disease

  15. Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma (TA661)

    Evidence-based recommendations on pembrolizumab (Keytruda) for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) in a

  16. Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer (TA653)

    Evidence-based recommendations on osimertinib (Tagrisso) for treating epidermal growth factor receptor (EGFR) T790M mutation-positive locally advanced or